# Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Study · id `cardio:ct-nct02984982` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02984982](<https://clinicaltrials.gov/study/NCT02984982>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02984982

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

## Technical summary

Registry record NCT02984982. Randomized; no masking; primary purpose treatment. Start 2016-11-15 (actual); primary completion 2018-07-27 (actual). Results posted on 2019-09-09.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 206 participants (enrolled count; ClinicalTrials.gov record NCT02984982, source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)
- Started: 2016-11-15 (actual) (ClinicalTrials.gov record NCT02984982, source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)
- Primary completion: 2018-07-27 (actual) (ClinicalTrials.gov record NCT02984982, source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)
- Completion: 2018-07-27 (actual) (ClinicalTrials.gov record NCT02984982, source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)
- Results first posted: 2019-09-09 (ClinicalTrials.gov record NCT02984982, source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT02984982, source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02984982-2019-09-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
- Acronym: ODYSSEY J-IVUS
- Condition: Hypercholesterolemia
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Alirocumab SAR236553
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Fenofibrate
- Intervention (Drug): Bezafibrate
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Antiplatelets
- Intervention (Drug): Anticoagulants
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry intervention name matches this record: Antiplatelet drugs (`cardio:antiplatelet-drugs`)
- Registry intervention name matches this record: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial (`cardio:pubmed-31434809`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0d15326036b6fdfca938899cdf4e195238861da606325012ee5ab33e477ba067
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
